Herpes Labialis (Oral Herpes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Herpes Labialis (Oral Herpes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Labialis (Oral Herpes) - Drugs In Development, 2022, provides an overview of the Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline landscape.

Oral herpes is an infection of the lips, mouth, or gums due to the herpes simplex virus. Oral herpes is also called herpes labialis. Symptoms include sore throat, fever, swollen glands and painful swallowing. Treatment includes antiviral medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Herpes Labialis (Oral Herpes) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Herpes Labialis (Oral Herpes) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 5 and 1 respectively.

Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Labialis (Oral Herpes) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Herpes Labialis (Oral Herpes) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Herpes Labialis (Oral Herpes) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Herpes Labialis (Oral Herpes) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Labialis (Oral Herpes) (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Herpes Labialis (Oral Herpes) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Herpes Labialis (Oral Herpes) – Overview
Herpes Labialis (Oral Herpes) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Herpes Labialis (Oral Herpes) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Herpes Labialis (Oral Herpes) – Companies Involved in Therapeutics Development
AiCuris Anti-infective Cures AG
Astellas Pharma Inc
Brandenburg Antiinfektiva GmbH
Dobecure SL
Heidelberg Immunotherapeutics Gmbh
Jupiter Wellness Inc
NanoViricides Inc
Rational Vaccines Inc
Shulov Innovative Science Ltd
Vironova Medical AB
Herpes Labialis (Oral Herpes) – Drug Profiles
amenamevir – Drug Profile
Aspidasept – Drug Profile
B-220 – Drug Profile
Cold Sores – Drug Profile
ethamsylate – Drug Profile
HDIT-101 – Drug Profile
JW-100 – Drug Profile
JW-400 – Drug Profile
NVHHV-101 – Drug Profile
pritelivir – Drug Profile
RVX-101HSV1 – Drug Profile
ZEP-3 – Drug Profile
ZEP-4 – Drug Profile
Herpes Labialis (Oral Herpes) – Dormant Projects
Herpes Labialis (Oral Herpes) – Discontinued Products
Herpes Labialis (Oral Herpes) – Product Development Milestones
Featured News & Press Releases
Nov 17, 2020: Jupiter Wellness' JW-100 enters clinical trial for the treatment of Herpes
Aug 23, 2017: AiCuris Announces Final Patient Treated in Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes
Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes
Nov 05, 2010: AiCuris To Present Preclinical And Phase I Data Of Anti-HSV Drug AIC316 At Antivirals Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Herpes Labialis (Oral Herpes), 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Products under Development by Companies, 2022
Table 4: Number of Products by Stage and Target, 2022
Table 5: Number of Products by Stage and Mechanism of Action, 2022
Table 6: Number of Products by Stage and Route of Administration, 2022
Table 7: Number of Products by Stage and Molecule Type, 2022
Table 8: Herpes Labialis (Oral Herpes) – Pipeline by AiCuris Anti-infective Cures AG, 2022
Table 9: Herpes Labialis (Oral Herpes) – Pipeline by Astellas Pharma Inc, 2022
Table 10: Herpes Labialis (Oral Herpes) – Pipeline by Brandenburg Antiinfektiva GmbH, 2022
Table 11: Herpes Labialis (Oral Herpes) – Pipeline by Dobecure SL, 2022
Table 12: Herpes Labialis (Oral Herpes) – Pipeline by Heidelberg Immunotherapeutics Gmbh, 2022
Table 13: Herpes Labialis (Oral Herpes) – Pipeline by Jupiter Wellness Inc, 2022
Table 14: Herpes Labialis (Oral Herpes) – Pipeline by NanoViricides Inc, 2022
Table 15: Herpes Labialis (Oral Herpes) – Pipeline by Rational Vaccines Inc, 2022
Table 16: Herpes Labialis (Oral Herpes) – Pipeline by Shulov Innovative Science Ltd, 2022
Table 17: Herpes Labialis (Oral Herpes) – Pipeline by Vironova Medical AB, 2022
Table 18: Herpes Labialis (Oral Herpes) – Dormant Projects, 2022
Table 19: Herpes Labialis (Oral Herpes) – Discontinued Products, 2022
]
List of Figures
Figure 1: Number of Products under Development for Herpes Labialis (Oral Herpes), 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Targets, 2022
Figure 4: Number of Products by Stage and Targets, 2022
Figure 5: Number of Products by Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Mechanism of Actions, 2022
Figure 7: Number of Products by Routes of Administration, 2022
Figure 8: Number of Products by Stage and Routes of Administration, 2022
Figure 9: Number of Products by Molecule Types, 2022
Figure 10: Number of Products by Stage and Top 10 Molecule Types, 2022.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings